Experimental models of cardiac transplantation: Design determines relevance

Current Opinion in Organ Transplantation

Volumn 19, Issue 5, 2014, Pages 525-530

  Baldwin, William M ^a   Su, Charles A ^a   Shroka, Thomas M ^b   Fairchild, Robert L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Heterologous immunity; Humanized mice; Memory T cells

Indexed keywords

HISTOCOMPATIBILITY ANTIGEN;

ADAPTIVE IMMUNITY; CELL INFILTRATION; COLD ISCHEMIA; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; MEMORY CELL; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; REVIEW; ANIMAL; ANIMAL MODEL; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL MEMORY; T LYMPHOCYTE;

ANIMALS; GRAFT VS HOST DISEASE; HEART TRANSPLANTATION; HUMANS; IMMUNOLOGIC MEMORY; MODELS, ANIMAL; T-LYMPHOCYTES;

EID: 84925705023     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000113     Document Type: Review

References (63)

1. Groth CG, Brent LB, Calne RY, et al. Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles. World J Surg 2000;24:834-843.
2. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6:468-475.
3. Calne RY, White DJ, Rolles K, et al. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet 1978;1:1183-1185.
4. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5:443-453.
5. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-1264.
6. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992;89:11102-11105.
7. Wang H, Arp J, Liu W, et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007;179:4451-4463.
8. Chong AS, Alegre ML, Miller ML, Fairchild RL. Lessons and limits of mouse models. Cold Spring Harb Perspect Med 2013;3:a015495. This recent review includes discussions of mouse models of antibodymediated rejection and tolerance induction in kidney as well as in heart transplants.
9. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: how much of the promise has been realized? Nat Med 2005;11:605-613.
10. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002;2:501-509.
11. Schenk AD, Nozaki T, Rabant M, et al. Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008;8:1652-1661.
12. Atkinson C, Varela JC, Tomlinson S. Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res 2009;105:1094-1101.
13. Rabant M, Gorbacheva V, Fan R, et al. CD40-independent help by memory CD4 T cells induces pathogenic alloantibody but does not lead to long-lasting humoral immunity. Am J Transplant 2013;13:2831-2841. This study investigates the costimulation requirements for memory CD4 T cells to help B cells produce alloantibodies in the acute and chronic responses to heart transplants.
14. Su CA, Iida S, Abe T, Fairchild RL. Endogenous memory CD8 T cells directly mediate cardiac allograft rejection. Am J Transplant 2014;14:568-579. This study examines the clinically relevant effects of 4-8 h of cold ischemia on early immune responses to heart transplants.
15. Wade CM, Kulbokas EJ 3rd, Kirby AW, et al. The mosaic structure of variation in the laboratory mouse genome. Nature 2002;420:574-578.
16. Yang H, Wang JR, Didion JP, et al. Subspecific origin and haplotype diversity in the laboratory mouse. Nat Genet 2011;43:648-655.
17. Klein J. Histocompatibility-2 (H-2) polymorphism in wild mice. Science 1970;168:1362-1364.
18. Reichenbach DK, Li Q, Hoffman RA, et al. Allograft outcomes in outbred mice. Am J Transplant 2013;13:580-588. This study describes the wider spectrum of rejection that occurs when hearts are allografted in more genetically heterogeneous outbred mice.
19. Jones SW, Roberts RA, Robbins GR, et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J Clin Invest 2013;123:3061-3073. An important in-vivo study of the functional consequences of cytokine-induced macrophage polarization.
20. Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164:6166-6173.
21. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-2738.
22. Shay T, Jojic V, Zuk O, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A 2013;110:2946-2951. This study exploits an anatomical variation of the human heart to demonstrate the relevance of anatomical structure on pathological processes in the human coronary artery.
23. Petkova SB, Yuan R, Tsaih SW, et al. Genetic influence on immune phenotype revealed strain-specific variations in peripheral blood lineages. Physiol Genomics 2008;34:304-314.
24. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973;16:343-350.
25. Botta DM Jr, Elefteriades JA. Why are the intramyocardial portions of the coronary arteries spared from arteriosclerosis? Clinical implications. Int J Angiol 2009;18:59-61.
26. Loukas M, Bhatnagar A, Arumugam S, et al. Histologic and immunohistochemical analysis of the antiatherogenic effects of myocardial bridging in the adult human heart. Cardiovasc Pathol 2014;23:198-203.
27. Lu WH, Palatnik K, Fishbein GA, et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant 2011;30:1044-1050.
28. Wehner JR, Baldwin WM 3rd. Cardiac allograft vasculopathy: do adipocytes bridge alloimmune and metabolic risk factors? Curr Opin Organ Transplant 2010;15:639-644.
29. Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits: a report to the War Wounds Committee of the Medical Research Council. J Anat 1944;78(Pt 5):176-199.
30. Su CA, Fairchild RL. Memory T cells in transplantation. Curr Transplant Rep 2014;1:137-146. This article extensively reviewsmemory T cells in the context of organ transplantation.
31. Ayasoufi K, Yu H, Fan R, et al. Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactive memory T cells in mice. Am J Transplant 2013;13:589-599. This study analyzes the effects of a clinically relevant immunosuppressant on different types of T cells.
32. Neujahr DC, Chen C, Huang X, et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 2006;176:4632-4639.
33. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-474.
34. + T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000;69:2609-2612.
35. + T cells. J Immunol 2000;164:265-272.
36. Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001;167:5565-5573.
37. Augustine JJ, Siu DS, Clemente MJ, et al. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005;5:1971-1975.
38. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999;163:2267-2275.
39. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003;3:878-884.
40. Poggio ED, Clemente M, Riley J, et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004;15:1952-1960.
41. Braciale TJ, Andrew ME, Braciale VL. Simultaneous expression of H-2-restricted and alloreactive recognition by a cloned line of influenza virusspecific cytotoxic T lymphocytes. J Exp Med 1981;153:1371-1376.
42. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a pot-ent barrier to transplantation tolerance. J Clin Invest 2003;111:1887-1895.
43. Kitchens WH, Haridas D, Wagener ME, et al. Combined costimulatory and leukocyte functional antigen-1 blockade prevents transplant rejection mediated by heterologous immune memory alloresponses. Transplantation 2012;93:997-1005.
44. Kitchens WH, Haridas D, Wagener ME, et al. Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8 (+) memory T cells. Am J Transplant 2012;12:69-80.
45. Welsh RM, Markees TG, Woda BA, et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000;74:2210-2218.
46. Setoguchi K, Hattori Y, Iida S, et al. Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejection. Am J Transplant 2013;13:2293-2307.
47. Banner NR, Thomas HL, Curnow E, et al. The importance of cold and warm cardiac ischemia for survival after heart transplantation. Transplantation 2008;86:542-547.
48. Russo MJ, Chen JM, Sorabella RA, et al. The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2007;133:554-559.
49. Ishii D, Schenk AD, Baba S, Fairchild RL. Role of TNFalpha in early chemokine production and leukocyte infiltration into heart allografts. Am J Transplant 2010;10:59-68.
50. Setoguchi K, Schenk AD, Ishii D, et al. LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming. Am J Transplant 2011;11:923-935. In conjunction with reference 14, these experiments demonstrate that effects of endogenous memory T cells responses to cardiac allografts depend on variables related to the graft as well as the infiltrating T cells.
51. Mosier DE. Immunodeficient mice xenografted with human lymphoid cells: new models for in vivo studies of human immunobiology and infectious diseases. J Clin Immunol 1990;10:185-191.
52. Brehm MA, Shultz LD. Human allograft rejection in humanized mice: a historical perspective. Cell Mol Immunol 2012;9:225-231.
53. Hogenes M, Huibers M, Kroone C, De Weger R. Humanized mouse models in transplantation research. Transplant Rev (Orlando) 2014;28:103-110. This article extensively reviews humanized mouse models in the context of organ transplantation.
54. Koh KP, Wang Y, Yi T, et al. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest 2004;114:846-856.
55. Wang Y, Bai Y, Qin L, et al. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res 2007;101:560-569.
56. Rao DA, Eid RE, Qin L, et al. Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J Exp Med 2008;205:3145-3158.
57. Zhang J, Silva T, Yarovinsky T, et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010;107:408-417.
58. Yi T, Fogal B, Hao Z, et al. Reperfusion injury intensifies the adaptive human T cell alloresponse in a human-mouse chimeric artery model. Arterioscler Thromb Vasc Biol 2012;32:353-360.
59. Hester J, Schiopu A, Nadig SN, Wood KJ. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 2012;12:2008-2016.
60. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010;16:809-813.
61. Rathinam C, Poueymirou WT, Rojas J, et al. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 2011;118:3119-3128.
62. Rongvaux A, Willinger T, Takizawa H, et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proc Natl Acad Sci U S A 2011;108:2378-2383.
63. Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014;32:364-372.